Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 48, Issue 10, 1999, Pages 1236-1240

  Clemens, Andreas ^b   Klevesath, Martina S ^c   Hofmann, Marion ^c   Raulf, Friedrich ^c   Henkels, Mechthild ^c   Amiral, Jean ^c   Seibel, Markus J ^c   Zimmermann, Jürgen ^c   Ziegler, Reinhard ^c   Wahl, Peter ^c   Nawroth, Peter P ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HEMOGLOBIN A1C; OCTREOTIDE; SOMATOMEDIN C; THROMBOMODULIN;

ADULT; ARTICLE; CELL DAMAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; PROTEINURIA; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR DISEASE;

EID: 13044272899     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90261-5     Document Type: Article

References (34)

1. Marbach P, Briner U, Lemaire M, et al: From somatostatin to Sandostatin: Pharmacodynamics and pharmacokinetics. Metabolism 41:7-10, 1992
2. Meier R, Dierdorf R, Gyr K: Somatostatin-Analog (Octreotide) im klinischen Einsatz: Neuere und potentielle Indikationen. Schweiz Med Wochenschr 122:957-968, 1992
3. Lamberts SW, Van der Lely AJ, De Hederer WW, et al: Drug therapy octreotide. N Engl J Med 25:246-254, 1996
4. Jacobs ML, Derkx FHM, Stijnen T, et al: Effect of long-acting somatostatin analog (somatulin) on renal hyperfiltration in patients with IDDM. Diabetes Care 20:632-636, 1997
5. Grant MB, Caballero S, Millard WJ: Inhibition of IGF-1 and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: A potential treatment for ocular neovascularization. Regul Pept 48:267-278, 1993
6. Krassowski J, Rogala H, Jeske W, et al: The attenuated inhibitory action of octreotide, a somatostatin analogue, on GHRH-induced growth hormone response in type 1 diabetes mellitus. Horm Metab Res 28:207-208, 1996
7. Lunetta M, Di-Mauro M, Le-Moli R: Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: Reversal after mixing with aprotinin. J Endocrinol Invest 20:331-334, 1997
8. Reubi JC, Waser B, Markusse HM, et al: Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 271:371-378a, 1994
9. Reubi JC, Mazzuchelli L, Laissue J: Intestinal vessels express high density somatostatin receptors in human infammatory bowel disease. Gastroenterology 196:951-959, 1994
10. Ørskov H, Flyvbjerg A, Frystyk J, et al: Octreotide and diabetes: Theoretical and experimental aspects. Metabolism 41:66-71, 1992
11. Fisker S, Kaal A, Montini M, et al: Growth hormone binding protein and growth hormone availability in acromegalic patients with long-acting octreotide (Sandostatin-LAR). Eur J Endocrinol 136:61-66, 1997
12. Lundbæk K, Christensen NJ, Jensen VA: Diabetes, diabetic angiopathy, and growth hormone. Lancet 2:131-133,1970
13. Shumak SL, Grossman LD, Chew E, et al: Growth hormone suppression and nonproliferative diabetic retinopathy: A preliminary feasibility study. Clin Invest Med 13:287-292, 1990
14. Mallet B, Vialettes B, Haroche S, et al: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab 18:438-444, 1992
15. Harris AG, Gutniak M, Efendic S: Somatostatin analogue therapy of diabetes mellitus, in Bailey CJ, Flatt PR (eds): New Antidiabetic Drugs. 1990, pp 279-288
16. Grønbæk H, Nielsen B, Østerby R, et al: Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats. Diabetologia 38:135-144, 1995
17. Hyer SL, Sharp PS, Brooks RA, et al: Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol (Copenh) 120:187-194, 1989
18. Grønbæk H, Nielsen B, Frystyk J, et al: Effect of octreotide on experimental diabetic renal and glomerular growth: Importance of early intervention. J Endocrinol 147:95-102, 1995
19. Navascues I, Gil J, Pascau C, et al: Effect of a long-acting somatostatin derivate SMS 201-995 (Sandostatin) on glucose homeostasis in type I diabetes mellitus. Horm Res 29:92-94, 1988
20. Ørskov L, Møller N, Bak JF, et al: Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism 45:211-217, 1996
21. Ezzat S, Melmed S: Endocrine applications of the somatostatin analogue octreotide (Sandostatin). Metabolism 41:34-38, 1992
22. Nørgaard K, Snorgaard O, Jensen T, et al: Effects of octreotide on lipoproteins and endothelial function in type 1 (insulin-dependent) diabetic patients. Diabet Med 7:909-913, 1990
23. Raz I, Rubinger D, Popovtzer M, et al: Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats. Diabetes 47:924-930, 1998
24. Hirose T, Arita N, Otsuki M, et al: A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide. Intern Med 36:345-350, 1997
25. Chen JC, Hsiang YN, Buchan AM: Somatostatin receptor expression in rat iliac arteries after balloon injury. J Invest Surg 10:17-23, 1997
26. Flyvbjerg A, Marshall SM, Frystyk J, et al: Octreotide administration in diabetic rats: Effects on renal hypertrophy and urinary albumin excretion. Kidney Int 41:805-812, 1992
27. Igarashi K, Nakazawa I, Tani N, et al: Effect of a somatostatin analogue (SMS 201-995) on renal function and urinary protein excretion in diabetic rats. J Diabetes Complications 5:181-183, 1991
28. Serri O, Beauregard H, Brazeau P, et al: Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 265:888-892, 1991
29. Petersen MM, Christensen SE, Christiansen JS, et al: Acute effect of a somatostatin analogue on kidney function in type 1 diabetic patients. Diabet Med 7:304-309, 1990
30. Hergesell O, Andrassy K, Geberth S, et al: Plasma thrombomodulin levels are dependent on renal function. Thromb Res 72:455-458, 1993
31. Gabath SJ, Keller C, Kempe HP, et al: Plasma thrombomodulin: A marker of vascular complications in diabetes. Vasa 25:233-241, 1996
32. Ishii M, Uchiyama H, Kazama M: Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65:618-623, 1991
33. Tanaka A, Ishii H, Hiraishi S, et al: Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 37:269-272, 1991
34. Iwashima Y, Sato T, Watanabe K, et al: Elevation of plasma thrombomodulin levels in diabetic patients with early diabetic nephropathy. Diabetes 39:983-987, 1990